Clinical impact of an additional left ventricular lead in cardiac resynchronization therapy nonresponders: The V3 trial

Although addition of a second LV lead in CRT nonresponders is feasible with a high success rate, this approach is associated with a significant rate of severe adverse events and does not provide significant long-term clinical benefits (ClinicalTrials.gov Identifier No. NCT01059175).